18 Dec 2015 --- A new study by a team of researchers from New Zealand's University of Otago and Japan suggests that the appetite-regulating hormone ghrelin could be used clinically for the early treatment of critical limb ischemia (CLI), an advanced form of peripheral artery disease.
